1. miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape.
- Author
-
Chen, Fang, Zhao, Dandan, Xu, Yongfang, Zhang, Yi, Chen, Min-Hsuan, Pathak, Khyatiben, Hansen, Nate, Lovell, Brooke, Liang, Yong, Estrella, Katrina, Wang, Wei-Le, Ghoda, Lucy, Rockne, Russell, Wu, Xiwei, Ali, Haris, Yu, Jianhua, Caligiuri, Michael, Forman, Stephen, Trent, Jeff, Kuo, Ya-Huei, Li, Ling, Swiderski, Piotr, Zhang, Jianying, Kortylewski, Marcin, Nguyen, Le, Pirrotte, Patrick, Boldin, Mark, Marcucci, Guido, and Zhang, Bin
- Subjects
MicroRNAs ,Animals ,Blast Crisis ,Leukemia ,Myelogenous ,Chronic ,BCR-ABL Positive ,Humans ,Mice ,T-Lymphocytes ,Neoplastic Stem Cells ,Tumor Escape ,Female ,Interleukin-6 ,Cell Differentiation ,Mice ,Inbred C57BL - Abstract
We reported that an acquired miR-142 deficit transforms chronic phase (CP) chronic myeloid leukemia (CML) leukemic stem cells (LSCs) into blast crisis (BC) LSCs. Given the role of miR-142 in the development and activity of the immune system, we postulated that this deficit also promotes LSC immune escape. Herein, we report on IL-6-driven miR-142 deficit occurring in T cells during BC transformation. In CML murine models, miR-142 deficit impairs thymic differentiation of lymphoid-primed multipotent progenitors (LMPP) into T cells and prevents T cells metabolic reprogramming, thereby leading to loss of T cells and leukemia immune escape. Correcting miR-142 deficit with a miR-142 mimic compound (M-miR-142), alone or in combination with immune checkpoint antibodies, restores T cell number and immune activity, leading to LSC elimination and prolonged survival of BC CML murine and patient-derived xenograft models. These observations may open new therapeutic opportunities for BC CML and other myeloid malignancies.
- Published
- 2025